How to buy Lantern Pharma (LTRN) stock

Lantern Pharma Inc is a biotechnology business based in the US. Lantern Pharma shares (LTRN) are listed on the NASDAQ and all prices are listed in US Dollars. Lantern Pharma employs 11 staff and has a market cap (total outstanding shares value) of 0.00.

Lantern Pharma stock price (NASDAQ: LTRN)

Use our graph to track the performance of LTRN stocks over time.

Lantern Pharma shares at a glance

• Key figures

Information last updated 2021-07-22.

Latest market close	$15.12
52-week range	$10.40 - $23.50
50-day moving average	$14.61
200-day moving average	$16.20
Wall St. target price	$28.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.41

Buy Lantern Pharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Lantern Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Lantern Pharma Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lantern Pharma price performance over time

Historical closes compared with the close of $15.12 from 2021-05-28

1 week (2021-07-12)	8.78%
1 month (2021-06-23)	0.87%
3 months (2021-04-19)	N/A
6 months (2021-01-19)	N/A

1 year (2020-07-19)	N/A
2 years (2019-07-19)	N/A
3 years (2018-07-19)	N/A
5 years (2016-07-19)	N/A

Lantern Pharma financials

Gross profit TTM	$0
Return on assets TTM	-11.8%
Return on equity TTM	-19.17%
Profit margin	0%
Book value	$7.31
Market capitalisation	$155.9 million

TTM: trailing 12 months

Shorting Lantern Pharma shares

There are currently 334,476 Lantern Pharma shares held short by investors – that's known as Lantern Pharma's "short interest". This figure is 15.8% down from 397,142 last month.

There are a few different ways that this level of interest in shorting Lantern Pharma shares can be evaluated.

Lantern Pharma's "short interest ratio" (SIR)

Lantern Pharma's "short interest ratio" (SIR) is the quantity of Lantern Pharma shares currently shorted divided by the average quantity of Lantern Pharma shares traded daily (recently around 50297.142857143). Lantern Pharma's SIR currently stands at 6.65. In other words for every 100,000 Lantern Pharma shares traded daily on the market, roughly 6650 shares are currently held short.

However Lantern Pharma's short interest can also be evaluated against the total number of Lantern Pharma shares, or, against the total number of tradable Lantern Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lantern Pharma's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Lantern Pharma shares in existence, roughly 30 shares are currently held short) or 0.0572% of the tradable shares (for every 100,000 tradable Lantern Pharma shares, roughly 57 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Lantern Pharma.

Find out more about how you can short Lantern Pharma stock.

Lantern Pharma share dividends

We're not expecting Lantern Pharma to pay a dividend over the next 12 months.

Lantern Pharma overview

Lantern Pharma Inc. , a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas. .

Frequently asked questions

What percentage of Lantern Pharma is owned by insiders or institutions?
Currently 19.215% of Lantern Pharma shares are held by insiders and 34.67% by institutions. How many people work for Lantern Pharma?
Latest data suggests 11 work at Lantern Pharma. When does the fiscal year end for Lantern Pharma?
Lantern Pharma's fiscal year ends in December. Where is Lantern Pharma based?
Lantern Pharma's address is: 1920 McKinney Avenue, Dallas, TX, United States, 75201 What is Lantern Pharma's ISIN number?
Lantern Pharma's international securities identification number is: US51654W1018